Abstract
Acquired resistance of to the initial osimertinib (OSI) therapy remains a majormain issue in thefor treatment of in patients with epidermal growth factor receptor gene (EGFR) mutation-positivemutation positive non-small cell lung cancer (NSCLC) patients. Secondary EGFR mutations or co-existing uncommon EGFR uncommon mutations have been reported as a part of the resistanceresistant mechanisms for of osimertinibOSI. Afatinib (AFA) has a broad range of antitumor activitiesy for athe variety of EGFR mutations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
